StocksAutoliv IncALV

ALV

Autoliv Inc

78.33 2.27 (2.98%)
纳斯达克(NASDAQ)的延时价格 美元 市场开放
交易
78.33
78.56
已置顶的帖子
已修改
NordicEconomy
eToro Macro Insights: The ‘nordic model’ opportunity by Ben Laidler eToro's Global Markets Strategist. IDEA: 💡 Scandinavian stock markets have a long-term outperformance record (see chart), with a Nordic market the top developed world performer 7 of the past 15 years. This punches way-above their... 显示更多 翻译
市场动态消息
热门
DeepNews
$ALV (Autoliv Inc) Autoliv has refinanced its existing Revolving Credit Facility Autoliv (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems has refinanced its existing $1.1 billion revolving credit facility agreement maturing in July 2023. www.wkrn.com/business/press-releases/cision/20220523IO66045/autoliv-has-refinanced-its-existing-revolving-credit-facility/ 翻译
评论分享
null
.
DeepNews
$ALV (Autoliv Inc) Zacks: Analysts Expect Autoliv, Inc. (NYSE:ALV) Will Announce Earnings of $0.50 Per Share Brokerages forecast that Autoliv, Inc. (NYSE:ALV) will report $0.50 earnings per share (EPS) for the current quarter, according to Zacks. www.defenseworld.net/2022/05/19/zacks-analysts-expect-autoliv-inc-nysealv-will-announce-earnings-of-0-50-per-share.html 翻译
DeepNews
$ALV (Autoliv Inc) Autoliv, Inc. (NYSE:ALV) Sees Large Increase in Short Interest Autoliv, Inc. (NYSE:ALV) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 1.230,000 shares, a growth of 55.4% from the April 15th total of 791.300 shares.... 显示更多 翻译
DeepNews
$ALV (Autoliv Inc) Autoliv (ALV) – Research Analysts’ Recent Ratings Updates A number of research firms have changed their ratings and price targets for Autoliv (NYSE: ALV): 5/9/2022 – Autoliv was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. www.defenseworld.net/2022/05/11/autoliv-alv-research-analysts-recent-ratings-updates.html 翻译
Luciano Bolatti
🔗𝙈𝙖𝙧𝙠𝙚𝙩 𝙧𝙚𝙘𝙚𝙣𝙩 𝙣𝙚𝙬𝙨 - May 10th🔗 🔹️ $PFE (Pfizer) agreed to acquire Biohaven Pharmaceuticals (BHVN) for $148.50 per share in cash plus 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven's non-CGRP development stage pipeline compounds. 🔹️... 显示更多 翻译